181 related articles for article (PubMed ID: 23441760)
1. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
2. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
3. Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.
Geva R; Prenen H; Topal B; Aerts R; Vannoote J; Van Cutsem E
J Surg Oncol; 2010 Dec; 102(8):937-45. PubMed ID: 21165996
[TBL] [Abstract][Full Text] [Related]
4. Current issues in the targeted therapy of advanced colorectal cancer.
Knijn N; Tol J; Punt CJ
Discov Med; 2010 Apr; 9(47):328-36. PubMed ID: 20423677
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of EGFR and VEGF inhibition.
Pander J; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885
[TBL] [Abstract][Full Text] [Related]
6. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
Nygren P; Sørbye H; Osterlund P; Pfeiffer P
Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691
[TBL] [Abstract][Full Text] [Related]
7. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.
Italiano A
Oncology; 2006; 70(3):161-7. PubMed ID: 16675911
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
15. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
Saijo N
Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
17. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
18. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
20. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
